CN Bio raises $21 million to scale up organ-on-a-chip technology
CN Bio has raised $21 million in Series B financing to meet increasing demand for its organ-on-a-chip (OOC) solutions.
Stay updated with breaking news from Altis Biosystems. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CN Bio has raised $21 million in Series B financing to meet increasing demand for its organ-on-a-chip (OOC) solutions.
The 2024 Tweener List features: 54 new Triangle Tweeners, and a total of 300 Triangle Tweeners now being tracked and reported on.
CN Bio (Cambridge, UK) and Altis Biosystems, leading developers of in vitro human organ models, are partnering to create a primary human gut/liver microphysiological system (MPS) with inter-organ communication to mimic the oral drug administration route. Click to read more...
/PRNewswire/ -- Organ-on-Chip Market in terms of revenue was estimated to be worth $123,285 thousand in 2024 and is poised to reach $631,073 thousand by 2029,...
CN Bio and Altis Biosystems, Inc. announces a new strategic partnership.